TVRD - Cara Therapeutics, Inc.
3.93
-0.090 -2.290%
Share volume: 53,467
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$4.02
-0.09
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-13-2024 | 08-14-2024 | 11-14-2024 | 03-11-2025 | 05-13-2025 | 08-14-2025 | 11-13-2025 | |
| Assets | ||||||||
| Total Assets | 90.099 M | 72.495 M | 51.329 M | 43.827 M | 38.947 M | 43.750 M | 39.021 M | |
| Current Assets | 81.225 M | 63.859 M | 47.912 M | 43.827 M | 38.947 M | 43.130 M | 38.443 M | |
| Inventories | 2.741 M | 1.644 M | 625.000 K | 900.000 K | 900.000 K | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 22.777 M | 7.379 M | 4.975 M | 0.000 | 0.000 | 20.346 M | 15.042 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 46.996 M | 49.239 M | 37.061 M | 37.903 M | 34.217 M | 20.648 M | 21.418 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 3.548 M | 3.490 M | 3.417 M | 0.000 | 0.000 | 68.000 K | 60.000 K | |
| Other Assets | 5.326 M | 5.146 M | 0.000 | 0.000 | 0.000 | 552.000 K | 518.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 90.099 M | 72.495 M | 51.329 M | 43.827 M | 38.947 M | 43.750 M | 39.021 M | |
| Total liabilities | 60.296 M | 60.897 M | 50.622 M | 48.420 M | 47.020 M | 10.823 M | 11.155 M | |
| Total current liabilities | 15.095 M | 13.901 M | 10.039 M | 3.972 M | 1.199 M | 10.678 M | 11.040 M | |
| Accounts Payable | 14.875 M | 13.733 M | 6.622 M | 3.972 M | 1.199 M | 2.425 M | 4.078 M | |
| Other liabilities | 45.201 M | 46.996 M | 40.583 M | 44.448 M | 45.821 M | 145.000 K | 115.000 K | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 45.201 M | 46.996 M | 40.583 M | 44.448 M | 45.821 M | 145.000 K | 115.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 29.803 M | 11.598 M | 707.000 K | -4.593 M | -8.073 M | 32.927 M | 27.866 M | |
| Common stock | 745.435 M | 747.176 M | 748.665 M | 751.019 M | 752.445 M | 130.588 M | 131.034 M | |
| Retained earnings | -715.441 M | -735.457 M | -747.933 M | -755.612 M | -760.518 M | -97.648 M | -103.175 M |